Contact
searchSearch
HMP Global

Hidradenitis Suppurativa

Featured Article

News
Comfort, Interest, and Therapy Choices Differ Between Hidradenitis Suppurativa Experts and Non-Experts in Complex Cases
12/20/2023
Lisa Kuhns, PhD, MD
“Although North American guidelines for HS management were recently published in 2019 from both the United States and Canadian HS Foundations, barriers to HS expertise among dermatologists still exist,” wrote coauthors.
“Although North American guidelines for HS management were recently published in 2019 from both the United States and Canadian HS Foundations, barriers to HS expertise among dermatologists still exist,” wrote coauthors.
“Although North American...
12/20/2023
First Report Managed Care
News
Two Genetic Variants Implicated in Risk of Hidradenitis Suppurativa
11/22/2023
Jolynn Tumolo
In a genetic correlation analysis, researchers found that inflammatory bowel disease, psoriasis, and type 2 diabetes may share certain genetic factors with hidradenitis suppurativa. However, additional studies are needed to shed light on...
In a genetic correlation analysis, researchers found that inflammatory bowel disease, psoriasis, and type 2 diabetes may share certain genetic factors with hidradenitis suppurativa. However, additional studies are needed to shed light on...
In a genetic correlation...
11/22/2023
First Report Managed Care
Quiz
The Impact of HS Diagnosis on Comorbidity Burden
10/27/2023
True or False: The comorbidity burden tends to decrease after HS diagnosis.
True or False: The comorbidity burden tends to decrease after HS diagnosis.
True or False: The comorbidity...
10/27/2023
First Report Managed Care
News
Costs, Comorbidity Burden High in US Patients With Hidradenitis Suppurativa
09/20/2023
Jolynn Tumolo
“Patients with HS may require comprehensive care strategies involving a multidisciplinary team of physicians to improve health while reducing health care expenditures,” researchers advised.
“Patients with HS may require comprehensive care strategies involving a multidisciplinary team of physicians to improve health while reducing health care expenditures,” researchers advised.
“Patients with HS may require...
09/20/2023
First Report Managed Care
News
HS: Targeted Therapies and Training May Improve Patient Quality of Life
08/31/2023
Danielle Sposato
Hidradenitis suppurativa treatment involves pharmacological and surgical options, but systemic treatment is restricted, with only adalimumab, an anti-TNF-a antibody, approved.
Hidradenitis suppurativa treatment involves pharmacological and surgical options, but systemic treatment is restricted, with only adalimumab, an anti-TNF-a antibody, approved.
Hidradenitis suppurativa...
08/31/2023
First Report Managed Care

Newsfeed

News
Comfort, Interest, and Therapy Choices Differ Between Hidradenitis Suppurativa Experts and Non-Experts in Complex Cases
12/20/2023
Lisa Kuhns, PhD, MD
“Although North American guidelines for HS management were recently published in 2019 from both the United States and Canadian HS Foundations, barriers to HS expertise among dermatologists still exist,” wrote coauthors.
“Although North American guidelines for HS management were recently published in 2019 from both the United States and Canadian HS Foundations, barriers to HS expertise among dermatologists still exist,” wrote coauthors.
“Although North American...
12/20/2023
First Report Managed Care
News
Two Genetic Variants Implicated in Risk of Hidradenitis Suppurativa
11/22/2023
Jolynn Tumolo
In a genetic correlation analysis, researchers found that inflammatory bowel disease, psoriasis, and type 2 diabetes may share certain genetic factors with hidradenitis suppurativa. However, additional studies are needed to shed light on...
In a genetic correlation analysis, researchers found that inflammatory bowel disease, psoriasis, and type 2 diabetes may share certain genetic factors with hidradenitis suppurativa. However, additional studies are needed to shed light on...
In a genetic correlation...
11/22/2023
First Report Managed Care
Quiz
The Impact of HS Diagnosis on Comorbidity Burden
10/27/2023
True or False: The comorbidity burden tends to decrease after HS diagnosis.
True or False: The comorbidity burden tends to decrease after HS diagnosis.
True or False: The comorbidity...
10/27/2023
First Report Managed Care
News
Costs, Comorbidity Burden High in US Patients With Hidradenitis Suppurativa
09/20/2023
Jolynn Tumolo
“Patients with HS may require comprehensive care strategies involving a multidisciplinary team of physicians to improve health while reducing health care expenditures,” researchers advised.
“Patients with HS may require comprehensive care strategies involving a multidisciplinary team of physicians to improve health while reducing health care expenditures,” researchers advised.
“Patients with HS may require...
09/20/2023
First Report Managed Care
News
HS: Targeted Therapies and Training May Improve Patient Quality of Life
08/31/2023
Danielle Sposato
Hidradenitis suppurativa treatment involves pharmacological and surgical options, but systemic treatment is restricted, with only adalimumab, an anti-TNF-a antibody, approved.
Hidradenitis suppurativa treatment involves pharmacological and surgical options, but systemic treatment is restricted, with only adalimumab, an anti-TNF-a antibody, approved.
Hidradenitis suppurativa...
08/31/2023
First Report Managed Care
Behind the Bill
CMS Expands Oversight and Competition Among Organ Procurement Organizations
11/06/2026
Grace Taylor, MS, MA
New Centers for Medicare & Medicaid Services (CMS) requirements address organ procurement safety, performance measurement, and service-area transitions, with implications for transplant access and care coordination.
New Centers for Medicare & Medicaid Services (CMS) requirements address organ procurement safety, performance measurement, and service-area transitions, with implications for transplant access and care coordination.
New Centers for Medicare &...
11/06/2026
First Report Managed Care
Conference Coverage
Semaglutide Associated With Reduced Liver Fibrosis Progression Risk
11/06/2026
Hannah Musick
A national study presented at AASLD 2026 found that semaglutide was associated with a 16% lower risk of liver fibrosis progression compared with dipeptidyl peptidase-4 inhibitors among veterans with metabolic dysfunction-associated steatotic...
A national study presented at AASLD 2026 found that semaglutide was associated with a 16% lower risk of liver fibrosis progression compared with dipeptidyl peptidase-4 inhibitors among veterans with metabolic dysfunction-associated steatotic...
A national study presented at...
11/06/2026
First Report Managed Care
News
MASH Treatment Model Projects Significant Economic Wastage With Low Semaglutide Persistence
11/06/2026
Rebecca Amrick
A study presented at AASLD TLM 2026 found that low adherence to optimal-dose semaglutide among patients with metabolic dysfunction-associated steatohepatitis (MASH) was projected to contribute to significant excess medical and pharmacy costs...
A study presented at AASLD TLM 2026 found that low adherence to optimal-dose semaglutide among patients with metabolic dysfunction-associated steatohepatitis (MASH) was projected to contribute to significant excess medical and pharmacy costs...
A study presented at AASLD TLM...
11/06/2026
First Report Managed Care
Conference Coverage
Semaglutide Associated With Greater Improvements in Liver Enzymes and Cardiometabolic Markers Than Resmetirom in MASH
11/05/2026
Hannah Musick
A real-world study presented at AASLD 2026 found that semaglutide was associated with greater reductions in liver enzymes, body weight, and hemoglobin A1c than resmetirom among patients with metabolic dysfunction-associated steatohepatitis,...
A real-world study presented at AASLD 2026 found that semaglutide was associated with greater reductions in liver enzymes, body weight, and hemoglobin A1c than resmetirom among patients with metabolic dysfunction-associated steatohepatitis,...
A real-world study presented at...
11/05/2026
First Report Managed Care
Conference Coverage
PharmD-Led Sub-Clinic Expands Semaglutide Access for Patients With MASLD
11/05/2026
Rebecca Amrick
A study presented at AASLD TLM 2026 found that a PharmD-led sub-clinic improved access to semaglutide and facilitated timely treatment initiation among patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
A study presented at AASLD TLM 2026 found that a PharmD-led sub-clinic improved access to semaglutide and facilitated timely treatment initiation among patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
A study presented at AASLD TLM...
11/05/2026
First Report Managed Care
News
MASH Disease Progression Associated With Increased Economic Burden Among Medicare Beneficiaries
11/04/2026
Rebecca Amrick
A study of Medicare fee-for-service beneficiaries found that those with metabolic dysfunction-associated steatohepatitis (MASH) had higher health care utilization rates and medical costs compared to those without MASH, with the greatest...
A study of Medicare fee-for-service beneficiaries found that those with metabolic dysfunction-associated steatohepatitis (MASH) had higher health care utilization rates and medical costs compared to those without MASH, with the greatest...
A study of Medicare...
11/04/2026
First Report Managed Care
News
Real-World Evidence Highlights Broader Benefits of Omalizumab for Food Allergy Management
11/03/2026
Hannah Musick
A narrative review of real-world evidence suggests that omalizumab may improve food allergy management beyond preventing allergic reactions, with potential benefits for dietary flexibility, quality of life, and patients with complex allergic...
A narrative review of real-world evidence suggests that omalizumab may improve food allergy management beyond preventing allergic reactions, with potential benefits for dietary flexibility, quality of life, and patients with complex allergic...
A narrative review of real-world...
11/03/2026
First Report Managed Care
News
Direct Patient and Caregiver Engagement in Prior Authorization Linked to Care Delays
11/03/2026
Rebecca Amrick
Researchers found that direct patient and caregiver involvement in prior authorization procedures was associated with delayed or suboptimal care, highlighting the need for policy reform to reduce administrative burdens and improve access to...
Researchers found that direct patient and caregiver involvement in prior authorization procedures was associated with delayed or suboptimal care, highlighting the need for policy reform to reduce administrative burdens and improve access to...
Researchers found that direct...
11/03/2026
First Report Managed Care
Behind the Bill
HHS HTI-5 Final Rule Cuts Health IT Requirements With $1.5 Billion in Projected Savings
10/30/2026
Grace Taylor, MS, MA
The US Department of Health and Human Services’ (HHS) Health Data, Technology, and Interoperability (HTI-5) final rule reduces health IT certification requirements and projects substantial regulatory savings while leaving proposed...
The US Department of Health and Human Services’ (HHS) Health Data, Technology, and Interoperability (HTI-5) final rule reduces health IT certification requirements and projects substantial regulatory savings while leaving proposed...
The US Department of Health and...
10/30/2026
First Report Managed Care
News
Suboptimal TKI Adherence Across Payer Types Among Patients With CML
10/30/2026
Rebecca Amrick
A comparison of insurance types showed that tyrosine kinase inhibitor (TKI) approval for patients with chronic myeloid leukemia (CML) was higher among Medicare and Medicaid beneficiaries, but treatment adherence remained suboptimal across...
A comparison of insurance types showed that tyrosine kinase inhibitor (TKI) approval for patients with chronic myeloid leukemia (CML) was higher among Medicare and Medicaid beneficiaries, but treatment adherence remained suboptimal across...
A comparison of insurance types...
10/30/2026
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use